The Scientific World Journal / 2013 / Article / Tab 4

Review Article

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

Table 4

Clinical trials on treatment with donepezil in moderate-severe AD.

First author and number in the list of references Severity Mean age yearsMean MMSE at baselineDuration
of the study
Test

Carrasco et al. 2011 [23]MMSE 1–2374.4 (7.7)Mild: 20.14 (4) 
Moderate: 15.9 (3.83) 
Severe: 11.3 (5.4)
6 months 455MMSE
NPI

Farlow et al. 2011, 2010 [24, 25]MMSE 0–2010 mg: 73.8 (8.56) 
23 mg: 73.9 (8.53)
10 mg: 13.0 (4.75) 
23 mg: 13.1 (4.99)
24 weeks1434MMSE
ACDS-ADL-sev
SIB
CIBIC-plus

Schwam and Xu 2010 [26]MMSE 5–17Placebo: 74 
Donepezil: 73.3
Placebo:   
Donepezil:
24 weeks290NPI
SIB
CIBIC-plus
MMSE
DAD

Homma et al. 2008 [27]MMSE Placebo:
5 mg:
10 mg:
Placebo:
5 mg:
10 mg:
24 weeks325BEHAVE-AD
ACDS-ADL-sev
CIBIC-plus
MMSE
SIB

Black et al. 2007 [28]MMSE 78.0 (8.10)Donepezil: 7.5 (325) 
Placebo: 7.4 (3.57)
24 weeks343ACDS-ADL-sev
CIBIC-plus
MMSE
SIB
NPI
CBQ

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.